12:00 AM
 | 
Dec 07, 2015
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Helsinn, Eisai sales and marketing update

Helsinn and Eisai said the American Society of Clinical Oncology (ASCO) has recognized Akynzeo netupitant/palonosetron as an option...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >